New test could flag which men need aggressive prostate cancer treatment and which don't

A new diagnostic test could improve the prostate cancer experience for millions of men.

Researchers at University College London (UCL) analyzed a tissue-based molecular test called Decipher to determine which men with high-risk prostate cancer were most likely to benefit from stronger treatment — and which might avoid unnecessary medication and side effects.

The analysis focused on abiraterone, a hormone therapy that was shown in the STAMPEDE clinical trial to cut the risk of death in half among men with high-risk...